Post a Comment Print Share on Facebook
Featured UE Pedro Sánchez PP Estados Unidos Sumar

RELEASE: European Wellness leads pioneering research on Down syndrome at the University of Heidelberg

(Information sent by the signatory company).

- 4 reads.

RELEASE: European Wellness leads pioneering research on Down syndrome at the University of Heidelberg

(Information sent by the signatory company)

HEIDELBERG, Germany, April 18, 2024 /PRNewswire/ -- European Wellness Biomedical Group (EWBG), in collaboration with the European Wellness Academy (EWA), Baden Research Laboratory and Heidelberg University, has announced substantial advances in Down syndrome research, revealing new neuroanatomical knowledge that opens the way to new treatment methods.

This groundbreaking study, conducted by pioneers in bioregenerative medicine and education, uses modern MRI methods to demonstrate a relationship between cognitive ability and brain volume changes in people with Down syndrome. These findings suggest that early intervention techniques improve the quality of life of affected people.

EWBG, known for its pioneering work in stem cell therapy, has been at the forefront of this study, in close collaboration with the University of Heidelberg. This collaboration demonstrates a shared commitment to transform the care and treatment of Down syndrome and associated diseases through cutting-edge scientific advances.

Professor and Dr. Mike Chan, a key collaborator in the study, highlighted the importance of bioregenerative medicine in this research. "Our findings represent a huge step forward in the understanding of Down syndrome," said Professor Mike Chan, PhD. "Through the application of stem cell therapy and other advanced treatments, we envision a future where personalized care can significantly improve outcomes for these individuals."

The European Wellbeing Academy is instrumental in providing advanced training to healthcare professionals involved in this research, ensuring that the latest advances in bioregenerative medicine are incorporated into clinical practices. Meanwhile, Baden is focused on creating an enabling environment for research and Heidelberg University is growing as a world leader in stem cell research and immunology, advancing study goals.

This joint project marks a turning point in Down syndrome research and sets a new standard for addressing and treating complicated neurological diseases. By harnessing the potential of bioregenerative medicine, partners are making strides toward a future where personalized, effective Down syndrome care is not just a possibility, but a reality.

CONTACT: EW Group Media Team,

Logo -

View original content: